Biogen Inc. (BIIB) was upgraded to a "buy" by TheStreet's Quant Ratings service on Wednesday. This biotech name has made a chart that could be challenging to many traders and investors. Let's drill down and see if an easier approach to the long side can be found.
More from Stocks
How Recency Bias and the Pareto Principle impact your trading decisions.
Fundamentals and valuations are secondary to shifting money into certain sectors.
Let's check in again on BAC after its latest earnings.
With the options open, I believe the near-term puts offer an attractive play.